- Clinical practice guidelines and real-world practice for hepatocellular carcinoma in Taiwan: Bridging the gap
-
Wang SY
- KMID: 2541414
- Clin Mol Hepatol.
- 2023 Apr;29(2):349-351.
- doi: 10.3350/cmh.2023.0082
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence on Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune tolerant phase”
-
Yoo JJ, Kim SG
- KMID: 2541440
- Clin Mol Hepatol.
- 2023 Apr;29(2):513-515.
- doi: 10.3350/cmh.2023.0044
-
- CITED
-
- Close
- SHARE
-
- Close
- Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future
-
Chuah KH, Chan WK
- KMID: 2541428
- Clin Mol Hepatol.
- 2023 Apr;29(2):401-403.
- doi: 10.3350/cmh.2023.0062
-
- CITED
-
- Close
- SHARE
-
- Close
- The current trends in the health burden of primary liver cancer across the globe
-
Konyn P, Ahmed A, Kim D
- KMID: 2541417
- Clin Mol Hepatol.
- 2023 Apr;29(2):358-362.
- doi: 10.3350/cmh.2023.0092
-
- CITED
-
- Close
- SHARE
-
- Close
- Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed
-
Kasper P, Demir M, Steffen HM
- KMID: 2541425
- Clin Mol Hepatol.
- 2023 Apr;29(2):390-393.
- doi: 10.3350/cmh.2023.0059
-
- CITED
-
- Close
- SHARE
-
- Close
- Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?
-
Teng ML, Tan DJH, Ng CH, Huang DQ
- KMID: 2541429
- Clin Mol Hepatol.
- 2023 Apr;29(2):404-407.
- doi: 10.3350/cmh.2023.0069
-
- CITED
-
- Close
- SHARE
-
- Close
- Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences
-
Yang T, Wang MD, Xu XF, Li C, Wu H, Shen F
- KMID: 2541412
- Clin Mol Hepatol.
- 2023 Apr;29(2):342-344.
- doi: 10.3350/cmh.2023.0106
-
- CITED
-
- Close
- SHARE
-
- Close
- The clinical management of hepatocellular carcinoma in China: Progress and challenges
-
Shan S, Jia J
- KMID: 2541411
- Clin Mol Hepatol.
- 2023 Apr;29(2):339-341.
- doi: 10.3350/cmh.2023.0077
-
- CITED
-
- Close
- SHARE
-
- Close
- Non-obese or lean nonalcoholic fatty liver disease matters, but is it preventable or inevitable in light of its risk factors?
-
Jang H, Kim W
- KMID: 2541423
- Clin Mol Hepatol.
- 2023 Apr;29(2):381-383.
- doi: 10.3350/cmh.2023.0088
-
- CITED
-
- Close
- SHARE
-
- Close
- Toward user-friendly and evidence-based practice guidelines for hepatocellular carcinoma
-
Kim DY
- KMID: 2541410
- Clin Mol Hepatol.
- 2023 Apr;29(2):335-338.
- doi: 10.3350/cmh.2023.0107
-
- CITED
-
- Close
- SHARE
-
- Close
- Systemic therapy in advanced hepatocellular carcinoma
-
Ahn JC, Tran NH, Yang JD
- KMID: 2541441
- Clin Mol Hepatol.
- 2023 Apr;29(2):516-519.
- doi: 10.3350/cmh.2023.0051
-
- CITED
-
- Close
- SHARE
-
- Close
- Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase”
-
Chu CM, Liaw YF
- KMID: 2541439
- Clin Mol Hepatol.
- 2023 Apr;29(2):510-512.
- doi: 10.3350/cmh.2023.0018
-
- CITED
-
- Close
- SHARE
-
- Close
- How to optimize the outcome of liver transplantation for non-alcoholic fatty liver disease
-
Song BG, Sinn DH
- KMID: 2541431
- Clin Mol Hepatol.
- 2023 Apr;29(2):411-413.
- doi: 10.3350/cmh.2023.0058
-
- CITED
-
- Close
- SHARE
-
- Close
- The imitator of immune-tolerant chronic hepatitis B: A killer in disguise
-
Hur MH, Lee JH
- KMID: 2541418
- Clin Mol Hepatol.
- 2023 Apr;29(2):363-366.
- doi: 10.3350/cmh.2023.0079
-
- CITED
-
- Close
- SHARE
-
- Close
- What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?
-
Park MK, Kim YJ
- KMID: 2541409
- Clin Mol Hepatol.
- 2023 Apr;29(2):332-334.
- doi: 10.3350/cmh.2023.0080
-
- CITED
-
- Close
- SHARE
-
- Close
- The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review
-
Jin YJ
- KMID: 2541432
- Clin Mol Hepatol.
- 2023 Apr;29(2):414-416.
- doi: 10.3350/cmh.2023.0055
-
- CITED
-
- Close
- SHARE
-
- Close
- Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
-
Alnimer L, Noureddin M
- KMID: 2541426
- Clin Mol Hepatol.
- 2023 Apr;29(2):394-397.
- doi: 10.3350/cmh.2023.0104
-
- CITED
-
- Close
- SHARE
-
- Close
- The latest global burden of liver cancer: A past and present threat
-
Oh JH, Jun DW
- KMID: 2541416
- Clin Mol Hepatol.
- 2023 Apr;29(2):355-357.
- doi: 10.3350/cmh.2023.0070
-
- CITED
-
- Close
- SHARE
-
- Close
- Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology
-
Yoon EL, Jun DW
- KMID: 2541420
- Clin Mol Hepatol.
- 2023 Apr;29(2):371-373.
- doi: 10.3350/cmh.2023.0086
-
- CITED
-
- Close
- SHARE
-
- Close
- The growing burden of non-alcoholic fatty liver disease on mortality
-
Cho JY, Sohn W
- KMID: 2541421
- Clin Mol Hepatol.
- 2023 Apr;29(2):374-376.
- doi: 10.3350/cmh.2023.0084
-
- CITED
-
- Close
- SHARE
-
- Close
